SION (Sionna Therapeutics) Marketable Securities: $152.83 Mil (As of Mar. 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.12
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Marketable Securities?

Sionna Therapeutics SION -1.98% 12 Marketable Securities is $152.83 Mil as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sionna Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $152.83 Mil.

Sionna Therapeutics's annual Marketable Securities increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($109.75 Mil) and increased from Dec. 2024 ($109.75 Mil) to Dec. 2025 ($177.43 Mil).

Sionna Therapeutics  (NAS:SION) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sionna Therapeutics Marketable Securities Related Terms

Sionna Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Marketable Securities Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Marketable Securities
27.77 0.00 109.75 177.43

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 186.97 221.59 197.50 177.43 152.83
SION
12GF Score
Sionna Therapeutics Inc SION
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $152.83 Mil mean?
Sionna Therapeutics (SION) has a Marketable Securities of $152.83 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sionna Therapeutics and its competitors.
Is Sionna Therapeutics' Marketable Securities too high?
Sionna Therapeutics' current Marketable Securities is $152.83 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Marketable Securities compare to TYRA and RAPP?
Sionna Therapeutics' Marketable Securities of $152.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sionna Therapeutics and its competitors. Sionna Therapeutics's current Marketable Securities is $152.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Marketable Securities of $152.83 Mil. The current Marketable Securities is $152.83 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Marketable Securities is $152.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.12
Price